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Background and Aim: Human beta-defensin-2 (hBD-2) is an antimicrobial cationic peptide capable to control human carcinoma 
cell growth via cell cycle regulation. The present study was aimed on determination of hBD-2 influence on the growth patterns and 
malignant potential of cultured human melanoma cells. Methods: The study was performed on cultured human melanoma cells 
of mel Z and mel Is lines treated with recombinant hBD-2 (rec-hBD-2); cell viability, proliferation, cell cycle distribution, and 
anchorage-independent growth were analyzed using MTT test, direct cell counting, flow cytometry, and colony forming assay 
respectively. Expression and/or phosphorylation levels of proteins involved in cell cycle control were evaluated by Western blotting. 
Results: The treatment of mel Z and mel Is cells with rec-hBD-2 in a concentration range of 100–1000 nM resulted in a concen-
tration-dependent suppression of cell proliferation, viability, and colony forming activity. It has been shown that rec-hBD-2 exerts 
its growth suppression effects via significant downregulation of B-Raf expression, activation of pRB and upregulation of p21WAF1 ex-
pression, downregulation of cyclin D1 and cyclin E resulting in cell cycle arrest at G1/S checkpoint. Conclusion: According to ob-
tained results, hBD-2 exerts its growth suppression effect toward human melanoma cells via downregulation of B-Raf, cyclin D1 and 
cyclin E expression, upregulation of p21WAF1 expression and activation of pRB.
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Human melanoma is the most lethal form of skin 
cancer with constantly rising incidence worldwide. 
While early stage melanoma is curable, melanoma 
patients with advanced disease have poor prognosis 
because this type of cancer is resistant to chemothe-
rapy [1]. That’s why there is a need for the develop-
ment of new strategies for melanoma treatment.
Cationic antimicrobial peptides (CAPs) of eukaryotic 
origin are among many agents with potential anti-mel-
anoma activity. These peptide antibiotics are produced 
by many living species including mammals. CAPs are 
active against different bacterial pathogens, viruses, 
and fungi. Therapeutic potential of peptide antibiotics 
as anti-infective agents is considered pro mising despite 
the difficulties related to their pharmacokinetics, toxicity 
and immunogenicity [2]. Moreover, some of CAPs exert 
cytotoxic activity toward cancer cells. This ability of CAPs 
is thought to be related to the biophysical properties 
of their molecules, in particular high cationic charge and 
amphipathicity allowing interaction of CAP molecules 
with negatively charged cancer cell membranes and cell 
lysis [3]. The know ledge on cytotoxic activity of particular 
CAPs against cancer cells in vitro and in vivo has been 
gained. Moreover, a number of these peptides have 
been studied in experimental models as anticancer 
agents [4]. In particular, some antimicrobial peptides, like 
cathelicidin-BF from the venom of the snake Bungarus 
fasciatus [5], crotamine from the venom of Crotalus 
durissus terrificus rattlesnake [6], or gomesin from 
hemocytes of the spider Acanthoscurria gomesiana [7] 
have been demonstrated to be effective for experimental 
B16 melanoma treatment in vivo.
In humans, CAPs are represented by the host defense 
peptides of defensin family (human α- and β-defensins, 
hBDs) and cathelicidin LL-37, important components 
of innate immunity protecting organism from pathogens 
along with many other biologically active molecules [8, 9]. 
It has been assumed that hBDs and LL-37 play a critical 
role in antimicrobial protection of human skin and in wound 
healing processes, and dysregulation of hBDs expres-
sion (in particular, hBD-2) is implicated in pathogenesis 
of many skin pathologies, in particular, psoriasis and atopic 
dermatitis [10–12]. At the same time, despite the steady 
progress in understanding hBDs role in inflammatory 
skin disorders, little is known about possible implication 
of these peptides in the development of skin cancer.
It has been shown recently that in cutaneous squa-
mous cell carcinoma (SCC) hBD-1 is downregulated, 
while hBD-2 and hBD-3 are upregulated compared 
to healthy skin. So, the authors supposed that in SCC 
hBD-1 may play a role of tumor suppressor, while 
hBD-2 and hBD-3 may promote skin cancer develop-
ment [13]. However, hypothetically, the resulting effect 
of hBDs expression could depend on many factors, in-
cluding their local concentrations in particular tumor mi-
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croenvironment as far as these antimicrobials are shown 
to exert different effects in a concentration-dependent 
manner [14–17]. For example, hBD-2 and hBD-4 in low 
nanomolar concentration range stimulate carcinoma cell 
proliferation, but at higher doses are capable to block cell 
cycle and drastically suppress cancer cell growth in vitro 
[15, 17]. In high concentrations some human defensins 
exert potent cytotoxic activities against cancer cells in vi-
tro and in vivo, similarly to CAPs of other origin [18, 19].
Up-to-date, the effects of hBDs in physiological 
(nanomolar) concentration range on melanocytes and 
melanoma cells remains poorly studied. Melanoma arise 
from melanocytes, pigment dendritic cells located in epi-
dermis and hair follicles. Theoretically, their behavior 
could be regulated through paracrine way by defensins 
produced by neighboring keratinocytes. Indeed, it has 
been established that one of the inducible β-defensins, 
namely hBD-3, expression of which could be induced 
in keratinocytes by UVR [20], in low nanomolar concen-
trations exerts pigmentary effects and is a high-affinity 
ligand of melanocortin-1 receptor (MC1R). It is well 
recognized that MC1R is a receptor, which play a central 
role in pigmentation and in melanoma susceptibility in hu-
mans. It is supposed that hBD-3 may play an important 
role in melanocyte biology, response of human skin 
to UVR and skin cancer susceptibility [21, 22]. The ef-
fects of other hBDs on melanoma cells remain unknown.
In the present study we addressed a question whe-
ther exogenous recombinant hBD-2 (rec-hBD-2) could 
regulate the growth patterns and malignancy potential 
of cultured human melanoma cells. We have revealed 
that proliferation and viability of human melanoma cells 
are regulated by hBD-2 in a concentration-dependent 
manner. In particular, rec-hBD-2 in high nanomolar range 
suppresses viability and proliferation of melanoma cells 
via cell cycle arrest in G1/S checkpoint and markedly 
reduces their colony forming activity. Significant down-
regulation of B-Raf, cyclin E and cyclin D1 expression 
along with dephosphorylation of pRB in human mela-
noma cells treated with hBD-2 have been demonstrated. 
These data may be useful for further development of new 
approaches for melanoma treatment using CAPs.
MATERIALS AND METHODS
Cell lines and recombinant hBD-2 peptide. 
The study was carried out on 2 human melanoma cell 
lines — mel Z and mel Is, which were kindly provided 
by prof. A.Y. Baryshnikov (N.N. Blokhin Russian Cancer 
Research Center RAMS, Moscow, Russian Federa-
tion). Mel Z and mel Is cell lines were established from 
surgically resected metastatic lesions of patients with 
malignant disseminated melanoma by Dr. O.S. Bu-
rova (N.N. Blokhin Russian Cancer Research Center 
RAMS, Moscow, Russian Federation) [23].
Cell lines were cultured in DMEM culture medium 
supplemented with 10% fetal bovine serum (FBS), 
100 units/mL penicillin G sodium, 100 μg/mL streptomy-
cin sulfate in humidified 5% CO2 atmosphere at 37 oC.
To study the effect of exogenous defensin on cell 
growth, we used purified recombinant hBD-2 [24]. 
In brief, E. coli BL21(DE3) cells transformed with 
GST-hBD-2-recombinant plasmid were induced 
with 1 mM IPTG for 6 h, pelleted by centrifugation, 
resuspended in lysis buffer (50 mМ Tris-HCl, pH 7.6; 
250 mМ NaCl; 1% Triton Х-100 and cocktail of prote-
ase and phosphatase inhibitors), and disrupted using 
ultrasound disintegrator (UD-11 Automatic, Poland). 
Then cell lysate was applied to affinity chromatography 
on glutathione-agarose column (GE Healthcare, Swe-
den) with following cleavage of the defensin from fusion 
protein by thrombin digestion. hBD-2 peptide was fur-
ther purified by reverse phase chromatography on Sep-
Pack C18 cartridge (Waters, USA), vacuum-dried, and 
re-dissolved in acidified water. Protein concentration 
was determined by UV absorbance at 280 nm using 
spectrophotometer Nanodrop-1000 (USA).
Direct cell counting. To study the effect of rec-
hBD-2 on cell proliferation, mel Z and mel Is cells were 
routinely cultured in 24-well plates (5•104 cells per 
well) to nearly 50% confluence, then culture medium 
was replaced with fresh DMEM supplemented with 
2.5% FBS. Rec-hBD-2 was added into the medium 
in concentrations of 100, 500, or 1000 nM, followed 
by culturing for 48 h. After the treatment, cells were 
washed with PBS, detached with trypsin, and counted 
in hemocytometer. The percentage of dead cells was 
analyzed using trypan blue staining.
MT T assay. To evaluate the effect of rec-
hBD-2 on cell viability, MTT-test has been applied 
[25]. Mel Z and mel Is cells were seeded into 96-
well plates (7•103 cells per well) and incubated 
with rec-hBD-2 at the concentration range from 
1 pM to 2 μM in DMEM supplemented with 2.5% FBS 
for 48 h. Then cells were routinely treated with МТТ 
(3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetrazoli-
um bromide) according to standard protocol, and colo-
rimetric reaction was evaluated with the use of ELISA 
reader (Awareness Technology Inc, USA) at  = 545.
Flow cytometry analysis. Mel Z and mel Is cells 
were cultured in 10 cm Petri dishes in DMEM supple-
mented with 10% FBS to 50% confluence, then the me-
dium was replaced by the fresh DMEM supplemented 
with 2.5% FBS, and cells were treated with 1, 10, 100, 
500, or 1000 nM rec-hBD-2 for 48 h. After the treatment, 
the attached cells were washed with PBS, harvested 
by trypsinization, pelleted at 4 oC (500 g) for 5 min, 
washed twice in PBS, and resuspended in 1 ml of hy-
potonic cell lysis buffer (0.1% sodium citrate, 0.1% 
Triton X-100, 5 g/ml propidium iodide (Sigma, USA)). 
Cells were incubated at RT for 30 min in the dark, and 
cell cycle distribution was analyzed using cytometer 
Becton Dickinson FACS Calibur. The data were analyzed 
with the use of CellQuest software package and ModFit 
LT2.0 program (BDIS, USA) for Mac computers.
Western blot analysis. To analyze the level of ex-
pression and/or phosphorylation of some components 
of signaling pathways involved in cell cycle regulation, 
melanoma cells were cultured in 6-well plates and 
treated with 1000 nM rec-hBD-2 for 48 h as described 
above, washed with PBS and lyzed in RIPA buffer 
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with protease and phosphatase inhibitors. Proteins 
were separated in 9–22% gradient SDS-PAGE and 
transferred to nitrocellulose membrane Hybond-ECL, 
RPN3032D (Amersham Biosciences, USA). Nonspecific 
binding sites were blocked with 1Х PBS-Т, 5% milk solu-
tion for 3 h. Then the blots were incubated sequentially 
with primary Abs, and then with secondary polyclonal 
HRP-conjugated anti-rabbit IgG or anti-mouse IgG Abs 
(DakoCytomation, Denmark). The ECL Western blot-
ting detection system (Amersham Pharmacia Biotech) 
was used to reveal immunoreactivity. For Western blot-
ting, we have used antibodies against pRB, cyclin D1, 
phospho-pRB (S780), and CDK4 from Cell Signaling 
Tech (USA), p53 (IEPOR, Ukraine), p21WAF1 (Oncogene, 
USA), cyclin E, B-Raf (Santa-Cruz, USA), and beta-actin 
(Sigma, USA). All antibodies were used at the working 
dilutions accor ding to manufacturer instructions.
Colony forming assay and melanin content anal-
ysis. Substrate independent growth was studied by rou-
tine procedure [26]. The cells were seeded in 3 cm Petri 
dishes (5•103 cells) in the medium conta ining 0.5% 
methylcellulose, DMEM, 15% FBS with or without addi-
tion of 100, 500, or 1000 nM rec-hBD-2. After 2-weeks 
culturing in 5% СО2 at 37 оС, the developed colonies 
were stained with 0.01% neutral red in PBS for 30 min, 
and examined by light microscopy. TotalLab 2.0 pro-
gram (UK) has been used for data evaluation.
Melanin content in cultured human melanoma 
cells was analyzed using standard Fontana — Masson 
method [27].
Statistical analysis. The data are reported 
as the mean ± SD. Data on direct cell counting, MTT, 
flow cytometry analysis and colony forming assay were 
analyzed by Student’s t-test to assess the statistical 
significance of the difference between the groups. 
A statistically significant difference was considered 
to be present at p < 0.05.
RESULTS
The study has been performed in vitro using two hu-
man melanoma cell lines — mel Z cells originating from 
moderately differentiated melanoma, and mel Is origi-
nating from low differentiated melanoma [23].
The analysis of rec-hBD-2 effect on proli-
feration and viability of cultured human melanoma 
cells. To study the effect of rec-hBD-2 on growth rates 
of cultured melanoma cell lines, direct cell  counting 
technique has been used. Мel Z and mel Is cells 
were treated with rec-hBD-2 that was added into cell 
culture medium at different concentrations (100 nM, 
500 nM, 1 M) for 48 h. Rec-hBD-2 caused significant 
concentration-dependent suppression of mel Z proli-
feration (p < 0.05), while in mel Is cells growth suppres-
sion has been observed only in the case of treatment 
with 500 nM and 1 M rec-hBD-2 (p < 0.05) (Fig. 1). 
Effect of the defensin on melanoma cell proliferation 
was hBD-2-specific because preincubation of rec-
hBD-2 with anti-hBD-2 Abs (Santa-Cruz, USA) prior 
to its addition into cell culture medium completely 
abolished the above mentioned effects. According 
to the data of trypan blue staining, the percentage 
of dead cells in all samples didn’t exceed 3.5–4% for 
all tested rec-hBD-2 concentrations.
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Fig. 1. A concentration-dependent effect of rec-hBD-2 on the num-
ber of viable cultured human melanoma cells of mel Z and mel Is lines. 
Mel Z and mel Is cells were treated with rec-hBD-2 in concentra-
tions of 100 nM (columns 2), 500 nM (column 3), 1000 nM (column 
4); column 1 — control cells; column 5 — the cells were treated 
with 500 nM rec-hBD-2 after its 30 min preincubation with anti-
hBD-2 antibodies (Santa-Cruz, USA). The number of attached cells 
was evaluated by direct cell counting. The data of three independent 
experiments are presented as the mean ± SD. *The diffe rence 
is significant as compared to appropriate control (p < 0.05)
Next, we have analyzed the effect of rec-hBD-2 on vi-
ability of cultured mel Z and mel Is cells using MTT 
assay. It has been shown that at low concentrations 
(1 pM — 1 nM) rec-hBD-2 didn’t affect significantly 
viability of both cell lines, while treatment of the cells 
with higher concentrations of rec-hBD-2 (10 nM — 
1000 nM) resulted in significant dose-dependent de-
crease of cell viability (p < 0.05) (Fig. 2).
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Fig. 2. A concentration-dependent effect of rec-hBD-2 on viabi-
lity of mel Z and mel Is cells. Cell viability was evaluated by MTT 
analysis. The data of three independent experiments are present-
ed as the mean ± SD. *The difference is significant as compared 
to appropriate control (p < 0.05)
So, the data of direct cell counting and MTT de-
monstrated that low-differentiated melanoma mel Is cells 
are less sensitive to growth suppressing action of rec-
hBD-2 than moderately differentiated mel Z cells. An-
other important observation is an absence of apoptotic 
effects of the defensin toward cultured melanoma cells: 
the percentage of dead cells slightly differed between 
the samples treated with different hBD-2 concentra-
tions. This fact was further confirmed by the data of flow 
cytometry (see below) and analysis of PARP expression 
in hBD-2 treated melanoma cells (data not shown).
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Rec-hBD-2 affects cell cycle distribution and 
signaling pathways involved in cell cycle regulation 
in vitro. Flow cytometry analysis of cell cycle distribution 
of mel Z cells treated with 10–1000 nM rec-hBD-2 for 
48 h demonstrated a concentration-dependent cell 
growth arrest at G1/S checkpoint (p < 0.05) (Fig. 3). 
Similar results were registered for mel Is cells treated with 
rec-hBD-2 (data not shown). Treatment of melanoma 
cells with 10–1000 nM of hBD-2 did not affect the per-
centage of apoptotic cells (see Fig. 3).
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Fig. 3. Flow cytometry analysis of cell cycle distribution of mel Z cells 
treated with rec-hBD-2. Mel Z cells were treated with 1, 10, 100, 500, 
or 1000 nM rec-hBD-2 for 48 h. The data of two independent experi-
ments are presented as the mean ± SD. *The difference is significant 
compared to appropriate control (p < 0.05)
To explore the effect of rec-hBD-2 on the proteins 
involved in cell cycle regulation and cell growth control, 
the expression levels of cyclin D1, cyclin E, retino-
blastoma protein (pRB), CDK4, p21WAF1, p53, B-Raf 
and phosphorylation of pRB in mel Z and mel Is cells 
treated for 48 h with 1000 nM rec-hBD-2 in comparison 
to control (untreated) cells were studied using Western 
blotting. Treatment with rec-hBD-2 resulted in slight 
downregulation of pRB expression and its complete 
dephosphorylation. Moreover, we revealed suppres-
sion of cyclin D1 expression, significant downregula-
tion of cyclin E, CDK4 and B-Raf expression levels, and 
significant upregulation of p21WAF1 in hBD-2-treated 
melanoma cells. At the same time p53 expression level 
remained unaffected (Fig. 4).
Effect of rec-hBD-2 on colony-forming acti-
vity of human melanoma cells. We have performed 
colony forming assay to evaluate an effect of rec-
hBD-2 on anchorage-independent growth ability 
of human melanoma cells. It was shown that treatment 
with 100 nM of rec-hBD-2 resulted in insignificant de-
crease of colony numbers compared to control cells, 
addition of 500 nM of rec-hBD-2 into cell incubation 
medium significantly inhibited (p < 0.05) ability of mel 
Is cells to form colonies in semi-soft medium (Fig. 5), 
while in the pre sence of 1 M of the defensin no  visible 
colonies were developed. Also, rec-hBD-2 caused 
a concentration-dependent effect on anchorage-
independent growth of mel Z cells (data not shown).
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Fig. 4. Western blot analysis of expression levels of cyclin D1, 
cyclin E, pRB, CDK4, p53, B-Raf, and p21WAF1, and phosphory-
lation of pRB (ph-pRB) in mel Z and mel Is cells treated with 
1000 nM rec-hBD-2 for 48 h in comparison to control (untreated) 
cells (a). Graphic representations of Western blotting data cal-
culated with the use of TotalLab program (b)
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Fig. 5. Rec-hBD-2 significantly inhibits colony-forming activity 
of mel Is cells. The graph represents the numbers of colonies 
calculated with the use of TotalLab program
Melanin content in cultured human melanoma 
cells of mel Z and mel Is cells treated with 1 nM, 
100 nM or 500 nM rec-hBD-2 for 72 h was analyzed. 
We did not found alterations in melanin content 
in mel Z and mel Is cells treated with the defensin 
compared to control cells (data not shown). Thus, 
hBD-2 seems to be not involved in melanin synthesis 
regulation in cultured human melanoma cells.
DISCUSSION
In the present study we have shown that re-
combinant hBD-2, cationic host defense peptide, 
affects proliferation, viability, and cell cycle distribu-
tion of human melanoma cells in vitro. The effects 
of rec-hBD-2 on melanoma cell proliferation and 
viability were found to be similar to those in human 
A431 and A549 carcinoma cells [15]. Indeed, treatment 
of mel Z and mel Is cells with rec-hBD-2 at concentra-
tions higher than 100 nM resulted in significant inhibi-
tion of cell proliferation and viability evidently realized 
via cell cycle arrest at G1/S checkpoint.
The mechanism of cell division suppression 
by the defensin could be possibly based on inhibi-
tion of B-Raf expression and inactivation of signaling 
pathways controlled by this kinase. It is known that de-
creased expression of B-Raf affects activity of down-
stream kinases such as МЕК1 and ERK, and induction 
of transcription factors c-Fos, c-Jun and important 
mediator of growth factors effects — c-Myc, which 
in turn controls expression of cyclin D1 and CDK4 [28]. 
It’s necessary to note that treatment of melanoma cells 
with rec-hBD-2 resulted in complete down-regulation 
of cyclin D1 expression (see Fig. 4). In contrary to cy-
clins Е and В, the quantities of which after termination 
of their functioning during cell cycle progression de-
crease to minimal values, cyclin D1 expression remains 
at relatively high level — approximately equal to its 
half-maximal value in G1 phase [29].
According to our data (see Fig. 4), the possible 
mechanism of cell cycle arrest in G1/S checkpoint 
in melanoma cells treated with rec-hBD-2 could 
be based on activation (dephosphorylation) of pRB, 
down-regulation of cyclins D1 and E, and increased 
quantity of CDK inhibitor — р21WAF1. Up-regulation 
of р21WAF1 is difficult to explain because expres-
sion of р53 in the melanoma cells treated with rec-
hBD-2 did not alter significantly. It can not be excluded 
that an increase of р21WAF1 expression is realized via 
alternative, p53-independent mechanisms [30, 31].
The mechanism of growth-suppressing acti-
vity of rec-hBD-2 toward human melanoma cells 
in vitro was found to be similar to that in human 
A431 and 549 carcinoma cells — via cell cycle ar-
rest at G1/S checkpoint [15]. Therefore, this activity 
of the defensin is not cell-type specific.
In current study we found a significant influence 
of rec-hBD-2 on expression of B-Raf — an important 
serine/threonine kinase involved in regulation of cell 
growth. Mutations in BRAF gene resulting in constitu-
tive activation of the kinase are often observed in many 
human cancers, including melanoma [32]. Novel 
drugs, specific B-Raf inhibitors, have been developed; 
some of them (dabrafenib, vemurafenib) have been 
evaluated in clinical trials for melanoma treatment 
and the results of these trials are considered pro-
mising [33]. Our finding, which demonstrated a potent 
down-regulation of B-Raf expression in human mela-
noma cells in vitro caused by innate defense molecule 
hBD-2 can be potentially useful in the development 
of new agents for combined treatment of melanoma.
Also, our data have shown that rec-hBD-2 is ca-
pable to suppress an important hallmark of malig-
nant cells — their ability for anchorage-independent 
growth. Indeed, in the presence of 500 nM of rec-
hBD-2 the number of colonies formed by mel Z cells 
was nearly 10 fold lower that in the control (p < 0.05) 
(see Fig. 5). Similar ability to inhibit malignant potential 
of human cancer cells in vitro has been described re-
cently for human beta-defensin-4 — another inducible 
peptide antibiotic expressed by epithelial cells [17].
The results of our study raise new questions: 
do human melanoma cells express β-defensins, and 
could their behavior and growth patterns be affected 
by paracrine way through hBDs expressed by neigh-
boring skin keratinocytes? Unfortunately, little is known 
about expression of hBDs in normal melanocytes and 
malignant melanoma cells. At the same time, experi-
mental studies have provided evidence on responsive-
ness of melanocytes to the action of β-defensins. 
In particular, it has been demonstrated that some hu-
man β-defensins (hBD-1 and hBD-3) in low nanomolar 
concentrations are high-affinity ligands for MC1R 
in primary human melanocytes, and it has been sup-
posed that hBD-3 may activate MAPK and cAMP sig-
naling pathways via MC1R thus regulating melanocyte 
responses [22, 34]. In a recent  Spanish  case-control 
study [35] it has been shown that hBD-1 (but not 
hBD-3) could be involved in malignant melanoma 
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susceptibility as far as polymorphisms in hBD-1 gene 
may be associated with increased risk of melanoma. 
According to the data of our research, treatment with 
rec-hBD-2 had no influence on melanin production 
levels in mel Z and mel Is cells. At the same time, 
hBD-2 significantly affects melanoma cell growth pat-
terns and malignancy potential in vitro and hypotheti-
cally could be capable to exert such effects in vivo. 
It will be reasonable to study possible associations 
between hBD-2 expression patterns and/or genetic 
polymorphisms of its gene in malignant melanoma 
and the risk of the development of this type of cancer.
In conclusion, our data have shown that exo genous 
hBD-2 can regulate the growth patterns of human 
melanoma cells in a concentration-dependent manner. 
In particular, in medium-to-high nanomolar concentra-
tion range this peptide is capable to suppress viability 
and proliferation of melanoma cells via cell cycle arrest 
in G1/S checkpoint and to reduce significantly their 
colony forming activity. Importantly, growth-sup-
pressing activity of hBD-2 is mediated by significant 
down-regulation of B-Raf, cyclin E and cyclin D1 ex-
pression along with dephosphorylation of pRB in hu-
man melanoma cells. Together, these results provide 
new evidence on important role of hBD-2 in regulation 
of malignant potential of human melanoma cells.
COMPETING INTERESTS
Authors declare that they have no competing in-
terests.
ACKNOWLEDGEMENTS
This work was in part supported with grant 
0110U005758 of National Academy of Sciences 
of Ukraine “Fundamental Basis of Molecular and Cel-
lular Biotechnologies”.
REFERENCES
1. Davies MA, Liu P, McIntyre S, et al. Prognostic fac-
tors for survival in melanoma patients with brain metastases. 
Cancer 2011; 117: 1687–96.
2. Devocelle M. Targeted antimicrobial peptides. Front 
Immunol 2012; 3: 309.
3. Leuschner C, Hansel W. Membrane disrupting 
lytic peptides for cancer treatments. Curr Pharm Des 2004; 
10: 2299–310.
4. Hoskin DW, Ramamoorthy A. Studies on anticancer 
activities of antimicrobial peptides. Biochim Biophys Acta 
2008; 1778: 357–75.
5. Wang H, Ke M, Tian Y, et al. BF-30 selectively inhi-
bits melanoma cell proliferation via cytoplasmic membrane 
permeabilization and DNA-binding in vitro and in B16F10-
bearing mice. Eur J Pharmacol 2013; 707: 1–10.
6. Pereira A, Kerkis A, Hayashi MA, et al. Crotamine 
toxicity and efficacy in mouse models of melanoma. Expert 
Opin Investig Drugs 2011; 20: 1189–200.
7. Rodrigues EG, Dobroff AS, Cavarsan CF, et al. Ef-
fective topical treatment of subcutaneous murine B16F10-
Nex2 melanoma by the antimicrobial peptide gomesin. 
Neoplasia 2008; 10: 61–8.
8. Doss M, White MR, Tecle T, Hartshorn KL. Human 
defensins and LL-37 in mucosal immunity. J Leukoc Biol 
2010; 87: 79–92.
9. Weinberg A, Jin G, Sieg S, McCormick TS. The Yin and 
Yang of human beta-defensins in health and disease. Front 
Immunol 2012; 3: 294.
10. Schittek B, Paulmann M, Senyürek I, Steffen H. 
The role of antimicrobial peptides in human skin and in skin in-
fectious diseases. Infect Disord Drug Targets 2008; 8: 135–43.
11. Rupec RA, Boneberger S, Ruzicka T. What is really 
in control of skin immunity: lymphocytes, dendritic cells, 
or keratinocytes? facts and controversies. Clin Dermatol 2010; 
28: 62–6.
12. Steinstraesser L, Koehler T, Jacobsen F, et al. Host 
defense peptides in wound healing. Mol Med 2008; 14: 528–37.
13. Scola N, Gambichler T, Saklaoui H, et al. The ex-
pression of antimicrobial peptides is significantly altered 
in cutaneous squamous cell carcinoma and precursor lesions. 
Br J Dermatol 2012; 167: 591–7.
14. Baroni A, Donnarumma G, Paoletti I, et al. Antimicro-
bial human beta-defensin-2 stimulates migration, proliferation 
and tube formation of human umbilical vein endothelial cells. 
Peptides 2009; 30: 267–72.
15. Zhuravel E, Shestakova T, Efanova O, et al. Human 
beta-defensin-2 controls cell cycle in malignant epithelial 
cells: in vitro study. Exp Oncol 2011; 33: 114–21.
16. Niyonsaba F, Ushio H, Nakano N, et al. Antimicrobial 
peptides human beta-defensins stimulate epidermal keratinocyte 
migration, proliferation and production of proinflammatory cy-
tokines and chemokines. J Invest Dermatol 2007; 127: 594–604.
17. Gerashchenko OL, Zhuravel EV, Skachkova OV, et al. 
Biologic activities of recombinant human-beta-defensin-4 to-
ward cultured human cancer cells. Exp Oncol 2013; 35: 76–82.
18. Muller CA, Markovic-Lipkovski J, Klatt T, et al. Hu-
man alpha-defensins HNPs-1, -2, and -3 in renal cell carci-
noma: influences on tumor cell proliferation. Am J Pathol 
2002; 160: 1311–24.
19. Aarbiou J, Tjabringa GS, Verhoosel RM, et al. 
Mechanisms of cell death induced by the neutrophil antimi-
crobial peptides alpha-defensins and LL-37. Inflamm Res 
2006; 55: 119–27.
20. Glaser R, Navid F, Schuller W, et al. UV-B radiation 
induces the expression of antimicrobial peptides in human 
keratinocytes in vitro and in vivo. J Allergy Clin Immunol 
2009; 123: 1117–23.
21. Swope VB, Jameson JA, McFarland KL, et al. 
 Defining MC1R regulation in human melanocytes by its ago-
nist α-melanocortin and antagonists agouti sig naling protein 
and β-defensin 3. J Invest Dermatol 2012; 132: 2255–62.
22. Abdel-Malek ZA, Supp D. Beta-defensin 3: a novel 
and unexpected key that unlocks the melanocortin 1 recep-
tor. Pigment Cell Melanoma Res 2008; 21: 7–8.
23. Burova OS. Generation and characterization of hu-
man melanoma cell lines for the development of cancer vac-
cines. PhD Thesis. N.N. Blokhin Russian Cancer Scientific 
Center RAMS; 2010.
24. Lisovskiy IL, Markeeva NV, Shnitsar VM, et al. 
Produсtion of recombinant of hBD-2 — human antimi-
crobial peptide expressed in cervical and vulval cancer. Exp 
Oncol 2003; 25: 36–9.
25. Mosmann T. Rapid colorimetric assay for cellu-
lar growth and survival: application to proliferation and 
cytotoxi city assays. Immunol Methods 1983; 65: 55–63.
26. Xu MJ, Tsuji K, Ueda T, et al. Stimulation of mouse 
and human primitive hematopoiesis by murine embryonic 
aorta-gonad-mesonephros-derived stromal cell lines. Blood 
1998; 92: 2032–40.
27. Cook HC. Manual of Histological Demonstration 
Techniques. London: Butterworths; 1974.
Experimental Oncology 36, 17–23, 2014 (March) 23
28. Nelson J. Structure and function in cell signalling. 
Chichester: John Wiley & Sons Ltd; 2008.
29. Phalk S, Mzoughi S, Bezzi M, et al. p53-Independent 
regulation of p21Waf1/Cip1 expression and senescence 
by PRMT6. Nucl Acids Res 2012; 40: 9534–42.
30. Zuo S, Liu C, Wang J, et al. IGFBP-rP1 induces 
p21 expression through a p53-independent pathway, leading 
to cellular senescence of MCF-7 breast cancer cells. J Cancer 
Res Clin Oncol 2012; 138: 1045–55.
31. Adhikary S, Eilers M. Transcriptional regulation and 
transformation by Myc proteins. Nat Rev Mol Cell Biol 2005; 
6: 635–45.
32. Davies H, Bignell GR, Cox C, et al. Mutations 
of the BRAF gene in human cancer. Nature 2002; 417: 949–54.
33. Menzies AM, Long GV, Murali R. Dabrafenib and its 
potential for the treatment of metastatic melanoma. Drug Des 
Devel Ther 2012; 6: 391–405.
34. Beaumont KA, Smit DJ, Liu YY, et al. Melano-
cortin-1 receptor-mediated signalling pathways activated 
by NDP-MSH and HBD3 ligands. Pigment Cell Melanoma 
Res 2012; 25: 370–4.
35. Fernandez LP, Milne RL, Pita G, et al. Human beta-
defensins (HBD1 and HBD3) and malignant melanoma sus-
ceptibility. Melanoma Res 2009; 19: 340–1.
 Copyright © Experimental Oncology, 2014 
